Adjunctive Therapy For Motor Fluctuations In Parkinson's Disease Therapeutics
1. Comtan patent expiration
Treatment: Treatment of parkinson's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5446194 | ORION PHARMA | Pharmacologically active catechol derivatives |
Oct, 2013
(12 years ago) | |
| US6599530 | ORION PHARMA | Oral compacted composition comprising catechol derivatives |
Sep, 2018
(7 years ago) | |
Drugs and Companies using ENTACAPONE ingredient
Market Authorisation Date: 19 October, 1999
Dosage: TABLET
How can I launch a generic of COMTAN before it's drug patent expiration?
More Information on Dosage
COMTAN family patents
2. Ongentys patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes; Adjunctive t...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9630955 | AMNEAL | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(6 years from now) | |
| US8168793 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(3 years from now) | |
| US8907099 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357468 | AMNEAL | Medicaments for slowing Parkinson's disease |
May, 2035
(9 years from now) | |
| US9745290 | AMNEAL | Dosage regimen for COMT inhibitors |
Oct, 2027
(1 year, 8 months from now) | |
| US9550759 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(6 months from now) | |
| US8524746 | AMNEAL | Dosage regimen for COMT inhibitors |
Jul, 2029
(3 years from now) | |
| US10583130 | AMNEAL | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| US12129247 | AMNEAL | Administration regime for nitrocatechols |
Jan, 2032
(6 years from now) | |
| US10071085 | AMNEAL | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents